Methods of diagnosing hypophosphatemic disorders
First Claim
Patent Images
1. A method of diagnosing a hypophosphatemic disorder in a mammal, said method comprising (a) obtaining a biological sample from said mammal and (b) contacting said biological sample with a reagent that detects the level of fibroblast growth factor-23 (FGF23) polypeptide in said sample,wherein the FGF23 polypeptide is a polypeptide selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2, a polypeptide comprising the amino acid sequence of SEQ ID NO;
4, a polypeptide comprising an arginine-to-glutamine mutation at amino acid 176 (R176Q) relative to SEQ ID NO;
2, a polypeptide comprising an arginine-to-glutamine mutation at amino acid 179 (R179Q) relative to SEQ ID NO;
2, and a polypeptide comprising an arginine-to-tryptophan mutation at amino acid 179 (R179W) relative to SEQ ID NO;
2,wherein an elevated level of FGF23 polypeptide in said sample, relative to the level of FGF23 polypeptide in a sample obtained from a control mammal, is an indication that said mammal is afflicted with said hypophosphatemic disorder, thereby diagnosing said hypophosphatemic disorder in said mammal.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to methods of diagnosing hypophosphatemic disorders.
-
Citations
6 Claims
-
1. A method of diagnosing a hypophosphatemic disorder in a mammal, said method comprising (a) obtaining a biological sample from said mammal and (b) contacting said biological sample with a reagent that detects the level of fibroblast growth factor-23 (FGF23) polypeptide in said sample,
wherein the FGF23 polypeptide is a polypeptide selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO: - 2, a polypeptide comprising the amino acid sequence of SEQ ID NO;
4, a polypeptide comprising an arginine-to-glutamine mutation at amino acid 176 (R176Q) relative to SEQ ID NO;
2, a polypeptide comprising an arginine-to-glutamine mutation at amino acid 179 (R179Q) relative to SEQ ID NO;
2, and a polypeptide comprising an arginine-to-tryptophan mutation at amino acid 179 (R179W) relative to SEQ ID NO;
2,wherein an elevated level of FGF23 polypeptide in said sample, relative to the level of FGF23 polypeptide in a sample obtained from a control mammal, is an indication that said mammal is afflicted with said hypophosphatemic disorder, thereby diagnosing said hypophosphatemic disorder in said mammal. - View Dependent Claims (2, 3, 4, 5, 6)
- 2, a polypeptide comprising the amino acid sequence of SEQ ID NO;
Specification